To download the certificate of analysis, please indicate your lot number below :Lot Number

Medium Performance

Fast: MRSA mauve Colonies in 18-24h.

Reliable: CHROMagar MRSA, introduced in 2002, was the first chromogenic medium for MRSA detection. It lead to such significant reductions in both, the response time and laboratory workload, that it allowed an absolutely necessary wide-scale patient screening.

High sensitivity: The medium exhibits sensitivity and specificity values close to 100%. CHROMagar MRSA allows an accurate detection of MRSA with a higher level of sensitivity than oxacillin containing media.

Easy interpretation: intense mauve colony colour.

Medium Description

All in one Version: Dehydrated culture media pack including a powder base and a supplement lyophilized. Simple to prepare, designed for end users who prepare their own plates.

Gain flexibility using powder rather than ready to use plates: Use the entire pack, or just a portion if there is a need for a smaller number of plates. If kept under appropriate storage temperature, CHROMagar MRSA has a 2 years shelf life. This flexibility is essential to avoid the waste resulting from expired- unused plates. For detailed preparation procedure, please refer to our IFU.

Plurivial version: Dehydrated culture media pack including a powder base A, a liquid supplement, a powder supplement and a supplement lyophilized. This version can be autoclaved, improving the sterility level of the plates, designed for ready to use plate manufacturers. For more information (detailed information, IFU, MSDS) on this product, please contact us.

Please refer to our IFU and Material Safety data sheet for complete information about the medium. CHROMagar™, Rambach™, AquaCHROM™ are trademarks created by Dr. A. Rambach. Last Update: 26-Oct-2017

Focus on MRSA

Over recent years, the occurrence of hospital infections caused by methicillin resistant Staphylococcus aureus (MRSA) has been increasing steadily, representing around 20 to 55% of the isolates in Europe and in the USA.Leading cause of nosocomial infections, especially in intensive care units, the MRSA sources are either endogenous (the patient) or through cross contamination (environmental or by person to person contact).The major issue with this pathogen is its resistance to a large panel of antibiotics, among them beta-lactam antibiotics, limiting the therapeutic options for clinicians.

MRSA Epidemiologic Issues

Early detection of patient contamination is essential for controlling
the spread of MRSA, providing appropriate care, and avoiding complex
and expensive treatments. Pre-admission screening for MRSA has proved
to be an effective method for reducing the hospital burden of
MRSA-colonised patients. The savings due to consistent decolonisation
before elective admission outweigh the costs of screening. Today, in
the US, the extra-expenses linked to difficult treatments of MRSA
infections are estimated at $2.4 billion for about 370,000 hospital
stays. (Genetic Engineering and Biotechnology News, August 2009). In the UK, the estimation of the additional cost of discharging every hospital patient who acquires MRSA is £9,000.

Implementation of Colorex MRSA/VRE bi-plate on WASP/WASPLab to screen for MRSA and VRE using Eswab duo swab